Foresite Capital Management V’s Maze Therapeutics MAZE Stock Holding History

Foresite Capital Management V’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$773K	Sell	25,905 -60,386	-70%	-$2.67M	0.29%	9
2025 Q4	$3.58M	Hold	86,291	–	–	2.17%	7
2025 Q3	$2.24M	Sell	86,291 -258,900	-75%	-$4.37M	2.06%	6
2025 Q2	$4.24M	Hold	345,191	–	–	5.25%	5
2025 Q1	$3.8M	Buy	+345,191	New	+$4.16M	4.34%	6

Other funds holding MAZE

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Foresite Capital Management V's MAZE Position: Q1 2026 in Review

Foresite Capital Management V reduced its Maze Therapeutics (MAZE) stake by 70% in Q1 2026, selling an estimated $2.67M and leaving 25,905 shares worth $773K. The position accounts for 0.29% of the portfolio, ranked #9.

Foresite Capital Management V first reported a position in MAZE in Q1 2025 and has held it in 5 quarters since. The position peaked at $4.24M in Q2 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

Foresite Capital Management V held 25,905 shares of Maze Therapeutics worth $773K as of Q1 2026.
Foresite Capital Management V sold 60,386 Maze Therapeutics shares in Q1 2026, an estimated $2.67M.
Maze Therapeutics made up 0.29% of Foresite Capital Management V's portfolio in Q1 2026, its #9 holding.
Foresite Capital Management V first reported a position in Maze Therapeutics in Q1 2025 and has held it in 5 quarters since.
Foresite Capital Management V's Maze Therapeutics position peaked at $4.24M in Q2 2025.
165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Foresite Capital Management V's 13F filing for Q1 2026, filed 15 May 2026.